Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: Results from a 14-week, randomized, double-blind, placebo-controlled study
Authors:
- Jon I. RussellJRJon I. Russell
- Andrew J. HolmanAHAndrew J. Holman
- Todd J. SwickTSTodd J. Swick
- Sarah Alvarez-HorineSASarah Alvarez-Horine
- Grace Y. WangGWGrace Y. Wang
- Diane GuintaDGDiane Guinta
- 1 May 2011
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Pain
- Vol. 152 (5) , 1007-1017
Abstract
This 14-week, phase 3, double-blind, randomized, controlled trial evaluated sodium oxybate (SXB) 4.5 and 6g per night versus placebo in patients with fibromyalgia (FM). SXB is the sodium salt of γ-hydroxybutyrate (GHB). GHB is an endogenous compound, synthesized from γ-aminobutyric acid (GABA) and found broadly in the central nervous system and body. Among 548 randomized patients, a ≥30% reduction in pain was experienced by 54.2% and 58.5% of patients treated with SXB 4.5 and 6g, respectively, versus 35.2% for placebo with a 100-mm Visual Analog Scale (VAS) (P<0.001 for both comparisons). Relative to placebo, both SXB doses significantly reduced fatigue (with a 100-mm VAS; P<0.001) and sleep disturbance (with the Jenkins Sleep Scale; P<0.001), and resulted in significant improvements in function as measured by the FM Impact Questionnaire (P=0.003 and P=0.001 for 4.5 and 6 g per night, respectively). On the Short-Form 36 Health Survey, SXB-related improvement was significant on the Physical, but not the Mental, Component Scale. The proportion of patients who reported a global improvement of "much" or "very much" better on the Patient Global Impression of Change was significantly greater in both SXB groups versus placebo (P<0.001). Headache, nausea, dizziness, vomiting, diarrhea, anxiety, and sinusitis were the most commonly reported adverse events, with an incidence at least twice that of placebo. These results expand the evidence from previous clinical trials suggesting that SXB is effective and safe in FM.Keywords
This publication has 42 references indexed in Scilit:
- Prevalence of Fibromyalgia: A Survey in Five European CountriesSeminars in Arthritis and Rheumatism, 2010
- Questioning the likelihood that sodium oxybate can be used to successfully treat fibromyalgia: Comment on the article by Russell et alArthritis & Rheumatism, 2009
- Minimal Clinically Important Difference in the Fibromyalgia Impact QuestionnaireThe Journal of Rheumatology, 2009
- Behavioral analyses of GHB: Receptor mechanismsPharmacology & Therapeutics, 2009
- Patient perspectives on the impact of fibromyalgiaPatient Education and Counseling, 2008
- Sleep stage dynamics in fibromyalgia patients and controlsSleep Medicine, 2008
- Sleep disturbances in fibromyalgia syndrome: Relationship to pain and depressionArthritis Care & Research, 2008
- Work Disability and Health System Utilization in Patients With Fibromyalgia SyndromeJCR: Journal of Clinical Rheumatology, 2007
- An internet survey of 2,596 people with fibromyalgiaBMC Musculoskeletal Disorders, 2007
- Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitisAnnals of the Rheumatic Diseases, 2005